Biotech News
Filter News
Found 487,463 articles
-
And now, this
6/20/2018
There are no words to describe and acknowledge this historic moment in Canada.
-
LUNGevity Foundation Kicks Off New Marketing Campaign to Raise Awareness of the Impact of Lung Cancer
6/13/2018
"234" asks the public to help change lung cancer statistics
-
Nicole Fevrier Davis Opens New MindBody Mastery Studio and Adds Psychic Assessments and Neurofeedback to her List of Unique Fitness Training Services
5/1/2018
Psychic personal trainer Nicole Fevrier Davis is slated to open her new studio at 10 Roberts Lane in Ridgefield CT on May 2nd.
-
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
-
Merck said it will lower the cost of one drug by 60 percent and several other drugs by 10 percent.
-
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
-
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
-
Agios Pharmaceuticals Scores FDA Approval For Tibsovo, Second AML Drug Win in Less Than a Year
7/20/2018
Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a year. -
The Institute for Life Science Entrepreneurship (ILSE) released a white paper highlighting life science incubator space and innovation trends in New Jersey. The report, entitled “Recent Advances in Laboratory and Innovation Space in New Jersey” profiles these efforts.
-
The U.S. Food and Drug Administration is looking to address supply chain threats by potentially importing foreign drugs under a narrow scope.
-
PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million.
-
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
-
Some diagnostics testing for infectious diseases can be quite invasive and uncomfortable for a patient. Now though, a new form of test is available that can mitigate the need for those invasive tests.
-
July 20 Research Roundup: PARPi and Rare Cancers, “Pleasure” Brain Chemicals and Cancer Suppressi...
7/20/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
7/20/2018
Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP
-
Alcon introduces NGENUITY® 3D Visualization System with DATAFUSION™ to simplify, customize vitreoretinal surgery
7/20/2018
Innovation to headline Alcon's presence at the American Society of Retina Specialists (ASRS) annual meeting
-
BIO Applauds Advancement of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
7/20/2018
Legislation would strengthen the pipeline and stockpile of medical countermeasures vital to our nation’s safety and defense
-
Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.
7/20/2018
Addition of FDA-cleared Sentinel® Cerebral Embolic Protection System to Expand Company's Structural Heart Offerings
-
Sobi™ strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune
7/20/2018
Swedish Orphan AB, an international biopharmaceutical company dedicated to rare diseases, and NovImmune SA have entered into an exclusive licence agreement for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis, developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.
-
U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)
7/20/2018
NIVESTYM™, a biosimilar to Neupogen® (filgrastim), is Pfizer’s fourth biosimilar to be approved by the FDA.